

INESSS invitations to submit a drug listing or re-evaluation request

When the Institut national d'excellence en santé et en services sociaux (INESSS) receives formal requests from patients, Quebec healthcare professionals, the MSSS or the RAMQ for the evaluation or re-evaluation of a drug, or a revision of reimbursement indications that it considers justified, it systematically invites the relevant manufacturers to submit a listing or re-evaluation request according to established standards, or to formally justify any refusal to do so. INESSS may also initiate such invitations when issues are identified regarding drug reimbursement in Quebec (e.g. product listing withdrawal).

Should a manufacturer fail to return a formal response (i.e. either a refusal or an approval) within 30 days following the invitation, the request status will automatically be changed to "Refused".

Invitations in 2024

Trademark	Common name	Name of the manufacturer	Indication	Type of request	Request status	Invitation date
Tafinlar / Mekinist	dabrafenib / trametinib	Novartis	LGG, HGG	Listing request	Refused	12-12-2024
Rydapt	midostaurin	Novartis	ASM, SM-AHN, MCL	Listing request	Refused	10-12-2024
Opdivo	nivolumab	B.M.S.	Hodgkin lymphoma	Listing request	Refused	10-12-2024
Spinraza	nusinersen	Biogen	Spinal muscular atrophy	Re-evaluation	Accepted - Evaluated	18-11-2024
Penicillin G sodium for injection, USP	penicillin G	Fresenius	Syphilis infections	Listing request	Refused	03-10-2024
Mylan-Azelastine / Fluticasone	azelastine / fluticasone	Mylan	Allergic rhinitis	Listing request	Accepted	03-10-2024
Dymista	azelastine / fluticasone	BGP Pharma	Allergic rhinitis	Listing request	Accepted	03-10-2024
Apo-Azelastine / Fluticasone	azelastine / fluticasone	Apotex	Allergic rhinitis	Listing request	Refused	03-10-2024

Taro-Adapalene / Benzoyl Peroxide	adapalene / benzoyl	Taro	Dual therapy acne	Listing request	Refused	01-10-2024
Taro-Adapalene / Benzoyl Peroxide Forte	adapalene / benzoyl	Taro	Dual therapy acne	Listing request	Refused	01-10-2024
Taro-Benzoyl Peroxide / Clindamycin Kit	clindamycin / benzoyl	Taro	Dual therapy acne	Listing request	Refused	01-10-2024
Sandoz Adapalene / Benzoyl Peroxide	adapalene / benzoyl	Sandoz	Dual therapy acne	Listing request	Refused	01-10-2024
Sandoz Adapalene / Benzoyl Peroxide Forte	adapalene / benzoyl	Sandoz	Dual therapy acne	Listing request	Refused	01-10-2024
Clindoxyl	clindamycin / benzoyl	GSK	Dual therapy acne	Listing request	Refused	01-10-2024
Tactupump	adapalene / benzoyl	Galderma	Dual therapy acne	Listing request	Refused	01-10-2024
Tactupump Forte	adapalene / benzoyl	Galderma	Dual therapy acne	Listing request	Refused	01-10-2024
Benzaclin	clindamycin / benzoyl	Bausch H.	Dual therapy acne	Listing request	Refused	01-10-2024
Benzamycin	erythromycin / benzoyl	Bausch H.	Dual therapy acne	Listing request	Refused	01-10-2024
Biacna	clindamycin / tretinoin	Bausch H.	Dual therapy acne	Listing request	Refused	01-10-2024
Ultibro Breezhaler	glycopyrronium / indacaterol	Novartis	COPD	Re-evaluation	Refused	19-08-2024
Inspiolto Respimat	olodaterol / tiotropium	Bo. Ing.	COPD	Re-evaluation	Refused	19-08-2024
Duaklir Genuair	formoterol dihydrate / aclidinium	Covis	COPD	Re-evaluation	Refused	19-08-2024
<u>Breztri Aerosphere</u>	formoterol dihydrate / budesonide / glycopyrronium	AZC	COPD	Re-evaluation	Accepted - Evaluated	19-08-2024

Trelegy Ellipta	umeclidinium / vilanterol / fluticasone	GSK	COPD	Re-evaluation	Refused	19-08-2024
Anoro Ellipta	umeclidinium / vilanterol	GSK	COPD	Re-evaluation	Refused	19-08-2024
JAMP-Sodium Phosphate	phosphorus / potassium / sodium	Jamp	Phosphorus supplementation	Listing request	Accepted - Evaluated	06-08-2024
Imitrex	sumatriptan	GSK	Migraine	Listing request	Refused	02-07-2024
Zomig	zolmitriptan	Xediton	Migraine	Listing request	Refused	02-07-2024
Zoledronic acid injection	zoledronic acid	Dr Reddy's	Osteoporosis in men	New indication	Refused	30-05-2024
Acide zolédronique injectable	zoledronic acid	Marcan	Osteoporosis in men	New indication	Refused	30-05-2024
Aclasta	zoledronic acid	Sandoz	Osteoporosis in men	New indication	Refused	30-05-2024
Injection d'acide zolédronique	zoledronic acid	Sun Pharma	Osteoporosis in men	New indication	Refused	30-05-2024
Penthrox	methoxyflurane	Paladin	Acute pain	Re-evaluation	Accepted - Evaluated	22-03-2024
Apo-Abiraterone	abiraterone	Apotex	CSPC	New indication	Accepted - Evaluated	12-02-2024
JAMP Abiraterone	abiraterone	Jamp	CSPC	New indication	Refused	12-02-2024
Mar-Abiraterone	abiraterone	Marcan	CSPC	New indication	Refused	12-02-2024
Nat-Abiraterone	abiraterone	Natco	CSPC	New indication	Refused	12-02-2024
pms-Abiraterone	abiraterone	Phmscience	CSPC	New indication	Refused	12-02-2024



Reddy-Abiraterone	abiraterone	Reddy's	CSPC	New indication	Refused	12-02-2024
Sandoz Abiraterone	abiraterone	Sandoz	CSPC	New indication	Refused	12-02-2024
Zytiga	abiraterone	Janss. Inc	CSPC	New indication	Refused	12-02-2024